Anthropic and OpenEvidence in September 2026 announced a partnership to make clinical AI decision support available free of charge in about 100 low- and middle-income countries. The service is intended for clinicians and is expected to account for local infrastructure, disease patterns and available treatments. The financial terms of the partnership were not disclosed.

The ambition addresses a genuine access problem. Clinicians in resource-constrained settings may have limited time, fragmented information and uneven access to specialist support. A tool that retrieves and synthesises relevant medical evidence could extend professional capacity. Free access can remove one barrier, but it does not establish clinical effectiveness or operational sustainability.

Localisation is more than translation

Clinical guidance developed in one health system may assume diagnostics, medicines, referral pathways and staffing that are unavailable elsewhere. Disease prevalence and public-health priorities also differ. A locally useful assistant must therefore adapt the evidence it presents and clearly state when a recommendation depends on resources that are not present.

Language quality is another requirement. Medical terminology, patient communication and local practice can vary within a country. Translation errors or unfamiliar phrasing may be consequential. Evaluation should include clinicians who work in the target settings, not only central technical teams. They should test common cases, rare but severe conditions, contraindications and situations in which the correct answer is to escalate.

Connectivity and device constraints influence safety as well. If the tool depends on reliable broadband, its availability may fail at the point of care. Offline or low-bandwidth design, update procedures and clear behaviour when sources cannot be retrieved should be considered. Privacy rules and expectations for patient data must be mapped country by country.

Governance for context-specific expert assistants

The service is described as decision support, so clinical responsibility remains with qualified professionals. That boundary should be visible in the interface and training. Users need citations, dates and an indication of uncertainty. High-risk recommendations should not be presented with greater confidence than the underlying evidence supports, and the product should make it easy to report unsafe or locally inappropriate outputs.

GBV recommends evaluating such deployments on four dimensions: factual and citation accuracy, clinical relevance in the local care pathway, accessibility under real infrastructure conditions and evidence of changed decisions or outcomes. Usage alone is not sufficient. The programme should publish enough information about testing and incident handling for local institutions to judge whether it fits their responsibilities.

For employers and benefits programmes, the partnership offers a wider lesson. Expert AI should be built from a controlled corpus, but its value depends on the rules, providers and resources surrounding the user. A global assistant needs jurisdiction-specific layers, local review and monitoring. Scale can distribute access; it cannot replace local evidence. The strongest model is a shared technical foundation combined with explicit adaptation, professional oversight and continuous evaluation in each context.

Sustainability follows access

A free launch still requires long-term funding for model operation, content licensing, localisation, security and clinical governance. Participating institutions should understand which functions are guaranteed, how service changes will be communicated and what happens to workflows if funding or access terms change. Dependency on a single tool can become an operational risk.

Local health authorities and professional bodies can help define acceptable use and training. Their involvement also creates a route for aggregating incident reports and identifying systematic gaps in evidence. The most credible expansion plan will publish what has been tested, where performance differs and how local findings change the product, rather than assuming that one central evaluation transfers everywhere.

The next review should test the recommendation against fresh operating evidence, identify any unintended consequences and record who owns the resulting action. That discipline keeps the proposal proportionate and allows governance to evolve as market practice, technology and regulation change.